Ziwei Xi1, Tong Liu1, Jing Liang1, Yu-Jie Zhou1, Wei Liu1. 1. Department of Cardiology, Beijing Anzhen hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing 100029, China.
Abstract
BACKGROUND: The incidence of conduction disturbances requiring permanent pacemaker (PPM) implantation following transcatheter aortic valve replacement (TAVR) have remained a common concern. The purpose of this study was to evaluate the impact of postprocedural PPM implantation following TAVR on clinical outcomes. METHODS: We performed a systematic search in PubMed and EMBASE databases for studies that reported raw data on clinical outcomes of patients with and without PPM implantation after TAVR and followed up patients for 10 months or longer. The primary endpoint was all-cause death. The secondary endpoints were cardiovascular death, heart failure and a composite of stroke and myocardial infarction (MI). RESULTS: Data from 20 studies with a total of 21,666 patients undergoing TAVR, of whom 12.5% required PPM implantation after intervention, were analysed and the mean duration follow-up was 16.9 months. The rate of PPM ranged from 6.2% to 32.8% among different studies. A total of 6,753 (31.2%) patients underwent TAVR with self-expandable prosthesis and 14,913 (68.8%) with balloon-expandable prosthesis. The incidence of postprocedural PPM implantation was higher with the self-expandable prosthesis (n=1,717, 25.4%) compared with the balloon-expandable prosthesis (n=996, 6.7%). PPM after TAVR was associated with a higher risk of all-cause death (RR: 1.13; 95% CI: 1.01-1.25; P=0.03) but not incidence of stroke and MI (RR: 0.85; 95% CI: 0.64-1.13; P=0.27). CONCLUSIONS: In patients undergoing TAVR, the PPM implantation after intervention was associated higher all-cause mortality but not cardiovascular mortality, heart failure and stroke or MI, which remain an unsolved issue of TAVR. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: The incidence of conduction disturbances requiring permanent pacemaker (PPM) implantation following transcatheter aortic valve replacement (TAVR) have remained a common concern. The purpose of this study was to evaluate the impact of postprocedural PPM implantation following TAVR on clinical outcomes. METHODS: We performed a systematic search in PubMed and EMBASE databases for studies that reported raw data on clinical outcomes of patients with and without PPM implantation after TAVR and followed up patients for 10 months or longer. The primary endpoint was all-cause death. The secondary endpoints were cardiovascular death, heart failure and a composite of stroke and myocardial infarction (MI). RESULTS: Data from 20 studies with a total of 21,666 patients undergoing TAVR, of whom 12.5% required PPM implantation after intervention, were analysed and the mean duration follow-up was 16.9 months. The rate of PPM ranged from 6.2% to 32.8% among different studies. A total of 6,753 (31.2%) patients underwent TAVR with self-expandable prosthesis and 14,913 (68.8%) with balloon-expandable prosthesis. The incidence of postprocedural PPM implantation was higher with the self-expandable prosthesis (n=1,717, 25.4%) compared with the balloon-expandable prosthesis (n=996, 6.7%). PPM after TAVR was associated with a higher risk of all-cause death (RR: 1.13; 95% CI: 1.01-1.25; P=0.03) but not incidence of stroke and MI (RR: 0.85; 95% CI: 0.64-1.13; P=0.27). CONCLUSIONS: In patients undergoing TAVR, the PPM implantation after intervention was associated higher all-cause mortality but not cardiovascular mortality, heart failure and stroke or MI, which remain an unsolved issue of TAVR. 2019 Journal of Thoracic Disease. All rights reserved.
Authors: Benjamin A Steinberg; J Kevin Harrison; Camille Frazier-Mills; G Chad Hughes; Jonathan P Piccini Journal: Am Heart J Date: 2012-10-02 Impact factor: 4.749
Authors: João Gonçalves Almeida; Sara Moura Ferreira; Paulo Fonseca; Tiago Dias; Cláudio Guerreiro; Ana Raquel Barbosa; Pedro Teixeira; Mónica Carvalho; Wilson Ferreira; Nuno Dias Ferreira; Marco Oliveira; Helena Gonçalves; Pedro Braga; José Ribeiro; João Primo; Vasco Gama Ribeiro Journal: J Cardiovasc Comput Tomogr Date: 2017-08-18
Authors: Justine M Ravaux; Sander M J Van Kuijk; Michele Di Mauro; Kevin Vernooy; Elham Bidar; Arnoud W Van't Hof; Leo Veenstra; Suzanne Kats; Saskia Houterman; Jos G Maessen; Roberto Lorusso Journal: J Clin Med Date: 2022-01-23 Impact factor: 4.241
Authors: Justine M Ravaux; Michele Di Mauro; Kevin Vernooy; Arnoud W Van't Hof; Leo Veenstra; Suzanne Kats; Jos G Maessen; Roberto Lorusso Journal: JTCVS Open Date: 2021-02-12